5-溴-N-[2-(4-吗啉基)乙基]-2-氨基吡啶 | 364794-56-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 5-溴-N-[2-(4-吗啉基)乙基]-2-氨基吡啶
• 英文名称: (5-bromopyridin-2-yl)-(2-morpholin-4-yl-ethyl)amine
• 英文别名: 5-Bromo-(2-morpholinoethylamino)pyridine；5-bromo-N-(2-morpholin-4-ylethyl)pyridin-2-amine
• CAS: 364794-56-9
• 化学式: C₁₁H₁₆BrN₃O
• mdl: MFCD09910232
• 分子量: 286.172
• InChiKey: OBYPVXGEXMMHLO-UHFFFAOYSA-N

物化性质

• 沸点：
  403.7±45.0 °C(Predicted)
• 密度：
  1.435±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.545
• 拓扑面积：
  37.4
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2934999090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 5-Bromo-(2-morpholinoethylamino)pyridine
Synonyms: 5-Bromo-N-(2-morpholinoethyl)pyridin-2-amine

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 5-Bromo-(2-morpholinoethylamino)pyridine
CAS number: 364794-56-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C11H16BrN3O
Molecular weight: 286.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-溴-N-[2-(4-吗啉基)乙基]-2-氨基吡啶 在 四(三苯基膦)钯 sodium carbonate 作用下， 以 1,4-二氧六环 、 乙醇 、 水 为溶剂， 反应 6.0h， 生成 4-(2-(5-(4-(2-oxo-2-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-ylamino)ethyl)phenyl)pyridin-2-ylamino)ethyl)morpholin-4-ium methanesulfonate
  参考文献：
  名称：

  [EN] BIARYL COMPOUNDS AND METHODS OF USE THEREOF
  [FR] COMPOSÉS BIARYLES ET PROCÉDÉS D'UTILISATION DE CEUX-CI

  摘要：

  本文提供了用于治疗KIT、CSF-1R和/或FLT3激酶介导疾病的化合物。还提供了包含这些化合物的药物组合物以及使用这些化合物和组合物的方法。

  公开号：

  WO2011022473A1
• 作为产物：
  描述：

  N-(2-氨基乙基)吗啉 、 2-氟-5-溴吡啶 在 对甲苯磺酸 silica gel 、 乙酸乙酯 作用下， 以 叔丁醇 为溶剂， 反应 16.0h， 以to afford 5-bromo-N-(2-morpholinoethyl)pyridin-2-amine (4.6 g, 55%) as a colorless oil的产率得到5-溴-N-[2-(4-吗啉基)乙基]-2-氨基吡啶
  参考文献：
  名称：

  BIARYL COMPOUNDS AND METHODS OF USE THEREOF

  摘要：

  本文提供了用于治疗KIT、CSF-1R和/或FLT3激酶介导的疾病的化合物。还提供了包含这些化合物的制药组合物以及使用这些化合物和组合物的方法。

  公开号：

  US20130035326A1

文献信息

• 3-CYANOQUINOLINES,3-CYANO-1,6-NAPHTHYRIDINES, AND 3-CYANO-1,7-NAPHTHYRIDINES AS PROTEIN KINASE INHIBITORS
  申请人：Wyeth

  公开号：EP1268431B1

  公开（公告）日：2007-08-29
• [EN] BIARYL COMPOUNDS AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS BIARYLES ET PROCÉDÉS D'UTILISATION DE CEUX-CI
  申请人：AMBIT BIOSCIENCES CORP

  公开号：WO2011022473A1

  公开（公告）日：2011-02-24

  Provided herein are compounds for treatment of KIT, CSF-1R and/or FLT3 kinase mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.

  本文提供了用于治疗KIT、CSF-1R和/或FLT3激酶介导疾病的化合物。还提供了包含这些化合物的药物组合物以及使用这些化合物和组合物的方法。
• BIARYL COMPOUNDS AND METHODS OF USE THEREOF
  申请人：Abraham Sunny

  公开号：US20130035326A1

  公开（公告）日：2013-02-07

  Provided herein are compounds for treatment of KIT, CSF-1R and/or FLT3 kinase mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.

  本文提供了用于治疗KIT、CSF-1R和/或FLT3激酶介导的疾病的化合物。还提供了包含这些化合物的制药组合物以及使用这些化合物和组合物的方法。